Coeptis Therapeutics, Inc.
NASDAQ:COEPBiotechnology
+$0.73 today
- Market cap
- $57.63M
- Beta
- -0.43
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$1.97
Volume 0.18M
Average 0.05M
COEP Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Coeptis Therapeutics, Inc.NASDAQ: COEP
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $250K fell 18.1% year over year, behind the +6.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 18.3% from the prior quarter. Over 3 fiscal years it compounded at +6.9% a year.
Context
- Depreciation & amortization amounted to 89.7% of revenue in FY2025.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -18.1% toward the trailing-twelve-month pace of +6.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.22M USD
- Year-over-year change
- +17.7%
- 4-year CAGR
- +28.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.22M | +17.7% |
| FY2024 | 2024-12-31 | 1.04M | +0.3% |
| FY2023 | 2023-12-31 | 1.04M | +3.4% |
| FY2022 | 2022-12-31 | 1M | +123.8% |
| FY2021 | 2021-12-31 | 447.41K | — |
Depreciation & Amortization vs competitors
How COEP compares with its peers on the latest reported figures
- COEP's LTM Mar 2026 depreciation & amortization of $1.17M is the 3rd highest of the 9 companies compared; the peer median is $246.5K.
- Its year-over-year change of +6.7% is the 4th highest of 9, against a peer median of +0.3%.
- Depreciation & amortization amounts to 82.6% of revenue for COEP, versus a peer median of 11.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.88M | -3.1% | +15.8% | — | |
| LTM Mar 2026 | $3.01M | +10.5% | +24.4% | 9.2% | |
| LTM Mar 2026 | $1.17M | +6.7% | +6.9% | 82.6% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $487.33K | +42.9% | +666.9% | — |
| LTM Mar 2026 | $306K | +6020.0% | +229.4% | 13.3% | |
| LTM Mar 2026 | $187K | -43.8% | -21.9% | 0.1% | |
| LTM Mar 2026 | $119.64K | +3.7% | -17.0% | 35.9% | |
| LTM Mar 2026 | $107K | -22.5% | -0.6% | — | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| Peer median (excluding COEP) | $246.5K | +0.3% | +15.8% | 11.3% | |
Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75K | 0 | 0 | 0 | 1.36M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 180.63K |
| Gross Profit | 75K | 0 | 0 | 0 | 1.18M |
| Gross Margin | 100.0% | — | — | — | 86.7% |
| Research & Development | 0 | 20.89K | 6.67M | 2.33M | 1.28M |
| Selling, General & Admin | 14.12M | 34.18M | 13.82M | 6.72M | 11.95M |
| Operating Expenses | 14.12M | 34.2M | 21.49M | 10.05M | 14.23M |
| Depreciation & Amortization | 447.41K | 1M | 1.04M | 1.04M | 1.22M |
| EBITDA | (12.81M) | (36.35M) | (20.12M) | (9.38M) | (10.41M) |
| EBITDA Margin | -17086.3% | — | — | — | -763.9% |
| Operating Income | (14.05M) | (34.2M) | (21.49M) | (10.05M) | (13.04M) |
| Operating Margin | -18727.9% | — | — | — | -956.9% |
| Interest Income | 0 | 0 | 0 | 0 | 116.5K |
| Interest Expense | 187.13K | 218.41K | 107.69K | 396.12K | 642.38K |
| Other Income / Expenses | 596.65K | (3.38M) | 224.59K | (822.92K) | 766.31K |
| Income Before Tax | (13.45M) | (37.57M) | (21.27M) | (10.88M) | (12.28M) |
| Pre-Tax Margin | -17932.4% | — | — | — | -900.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.45M) | (37.57M) | (21.27M) | (10.68M) | (11.92M) |
| Net Margin | -17932.4% | — | — | — | -874.3% |
| EPS (Basic) | (13.16) | (2.87) | (0.83) | (5.65) | (2.81) |
| EPS (Diluted) | (13.16) | (2.87) | (0.83) | (5.65) | (2.81) |
| Weighted Avg Shares | 1.02M | 14.3M | 25.69M | 1.93M | 4.23M |
| Weighted Avg Shares (Diluted) | 1.02M | 14.3M | 25.69M | 1.93M | 4.23M |
Coeptis Therapeutics, Inc.
NASDAQ:COEP
Intrinsic Alpha fair value
Locked
Current Price
$14.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.